Prodromal Symptoms of Multiple Sclerosis in Primary Care
Ann Neurol 83:1162-1173, Disanto,G.,et al, 2018
Multiple Sclerosis and Cannabis: A Cognitive and Psychiatric Study
Neurol 71:164-169, Ghaffar,O. &Feinstein,A., 2008
Neuropsychiatric Syndromes Associated With Multiple Sclerosis
J Neurol 254:II/73-II/76, Feinstein,A., 2007
Gray and White Matter Brain Atrophy and Neuropsychological Impairment in Multiple Sclerosis
Neurol 66:685-692, Sanfilipo,M.P.,et al, 2006
Cognitive Presentation of Multiple Sclerosis: Evidence for a Cortical Variant
JNNP 74:872-877, Zarei,M.,et al, 2003
Neuropsychological Status in Multiple Sclerosis after Treatment with Glatiramer
Arch Neurol 56:319-324, Weinstein,A.,et al, 1999
Serial Neuropsychological Assess & Magnetic Resonance Imagingf Analysis in Multiple Sclerosis
Arch Neurol 54:1018-1025, Hohol,M.J.,et al, 1997
Low-Dose Oral Methotrexate in Chronic Progressive Multiple Sclerosis:Analyses of Serial MRIs
Neurol 47:1153-1157, Goodkin,D.E.,et al, 1996
Information Processing Efficiency in Chronic Fatigue Syndromes and Multiple Sclerosis
Arch Neurol 50:301-304, DeLuca,J.,et al, 1993
Event-Related Potential P300 in MS, Relation to Magnetic Resonance Imaging and Cognitive Impairment
Arch Neurol 49:44-50, Honig,L.S.,et al, 1992
Cognitive Dysfunction in MS, II. Impact on Employment and Social Functioning
Neurol 41:692-696, Rao,S.M.,et al, 1991
Cognitive Loss in Multiple Sclerosis
Arch Neurol 46:162-167, Franklin,G.M.,et al, 1989
Correlation of Magnetic Resonance Imaging with Neuropsychological Testing in Multiple Sclerosis
Neurol 39:161-166, Rao,S.M.,et al, 1989
Correlation of Neuropsychological and MRI Findings in Chronic/Progressive Multiple Sclerosis
Neurol 38:1826-1829, Franklin,G.M.,et al, 1988
Cerebral Magnetic Resonance Imaging Findings in MS, Relation to Affect, Drive and Cognition
Arch Neurol 45:1114-1116, Reischies,F.M.,et al, 1988
Disease Activity & Emotional State in Multiple Sclerosis
Ann Neurol 13:573-577, Dalos,N.P.,et al, 1983
Psychological Profiles in Patients With Multiple Sclerosis, A Preliminary Investigation
Arch Neurol 37:437-440, Peyser,J.M.,et al, 1980
Cognitive Function in Patients With Multiple Sclerosis
Arch Neurol 37:577-579, Peyser,J.M.,et al, 1980
Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018
Dentate Update: Imaging Features of Entities that Affect the Dentate Nucleus
AJNR 38:1467-1474, Bond, K.M.,et al, 2017
The Contemporary Spectrum of Multiple Sclerosis Misdiagnosis
Neurol 87:1393-1399, Solomon, A.J.,et al, 2016
Daclizumab-Induced Adverse Events in Multiple Organ Systems in Multiple Sclerosis
Neurol 82:984-988, Oh, J.,et al, 2014
Cortical Pathology in Multiple Sclerosis Patients with Epilepsy: A 3 Year Longitudinal Study
JNNP 83:49-54, Calabrese, M.,et al, 2012
Severe Cutaneous Candida Infection During Natalizumab Therapy in Multiple Sclerosis
Neurol 74:521-523, Gutwinski,S.,et al, 2010
Dysexecutive Syndrome: Diagnostic Criteria and Validation Study
Ann Neurol 68:855-864, Godefroy,O.,et al, 2010
Clinicopath Conf, Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL)
NEJM 360:1656-1665, Case 12-2009, 2009
Memantine Induces Reversible Neurologic Impairment in Patients with MS
Neurol 72:1630-1633, Villoslada,P.,et al, 2009
Multiple Sclerosis with Predominant, Severe Cognitive Impairment
Arch Neurol 66:1139-1143, Staff,N.,et al, 2009
Glatiramer Acetate--Associated, CD30+, Primary, Cutaneous, Anaplastic Large-Cell Lymphoma
Arch Neurol 65:1378-1379, Madray,M.M.,et al, 2008
Thalamic Atrophy and Cognition in Multiple Sclerosis
Neurol 69:1213-1223, Houtchens,M.K.,et al, 2007
Pregnancy, Delivery, and Birth Outcome in Women with Multiple Sclerosis
Neurol 65:1961-1963, Dahl,J.,et al, 2005
Donepezil Improved Memory in Multiple Sclerosis in a Randomized Clinical Trial
Neurol 63:1579-1585, Krupp,L.B.,et al, 2004
Self Reported Stressful Life Events and Exacerbations in Multiple Sclerosis:Prospective Study
BMJ 327:646-649, Beljevac,D.,et al, 2003
The Influence of Cognitive Impairment on Driving Performance in Multiple Sclerosis
Neurol 56:1089-1094, Schultheis,M.R.,et al, 2001
Psychological Stress and the Subsequent Appearance of New Brain MRI Lesions in MS
Neurol 55:55-61, Mohr,D.C. et al, 2000
The Relationship of MS to Physical Trauma and Psychological Stress, Report of the Therapeutics and Technology Assessment Subcommittee of the AAN
Neurol 52:1737-1745, Goodin,D.S.,et al, 1999
Retinocochleocerebral Vasculopathy
Medicine 77:12-40, Petty,G.W.,et al, 1998
The Phenotypic Spectrum of CADASIL:Clinical Findings in 102 Cases,
Ann Neurol 44:731-739,715, Dichgans,M.,et al, 1998
Tolterodine for Overactive Bladder
The Medical Letter 40:101-102, , 1998
Palliative Care in Neurology
Neurol 46:870-872, 5981996., Bernat,J.L.,et al, 1996
Patients with Multiple Sclerosis Presenting to Psychiatric Hospitals
J Clin Psychiatry 56:297-306, Pine,D.S.,et al, 1995
The Effects of 4-Aminopyridine in MS Pts:Randomized, Placebo-Controlled, Double-Blind, Concentration-Controlled, Crossover
Neurol 44:1054-1059, Bever,C.T.,et al, 1994
Dementia in 2 Histologically Confirmed Cases of MS:One Isolated Dementia & One Assoc with Psychiatric Symptoms
JNNP 57:353-359, Fontaine,B.,et al, 1994
Psychological Stress as Risk Factor for Exacerbations in Multiple Sclerosis
Neurol 43:1311-1312, Nisipeanu,P.&Korczyn,A.D., 1993
Multiple Sclerosis with Very Late Onset
Neurol 42:1907-1910, Hooge,J.P.&Redekop,W.K., 1992
Uhthoff's Symptom in Optic Neuritis:Relationship to Magnetic Resonance Imaging & Development of Multiple Sclerosis
Ann Neurol 30:180-184, Scholl,G.B.,et al, 1991
Severely Threatening Events and Marked Life Difficulties Preceding Onset or Exacerbation of MS
JNNP 52:8-13, Grant,I.,et al, 1989
Dangers from Methylprednisolone Acetate Therapy by Intraspinal Injection
Arch Neurol 45:804-806, Nelson,D.A., 1988
Criteria for an Increased Specificity of MRI Interpretation in Elderly with Suspected Multiple Sclerosis
Neurol 38:1822-1825, Fazekas,F.,et al, 1988